ALXN's initiation of a rolling NDA for ALXN1840 in Wilson disease serves as a critical valuation catalyst, positioning the firm for potential regulatory approval.
AI-generated summary — powered by BigEarnings.
No confirmed earnings data available yet.
Showing last 0 quarters.